Safety of long-term treatment of HAM/TSP patients with valproic acid

Blood

Volumn 118, Issue 24, 2011, Pages 6306-6309

  Olindo, Stéphane ^a   Belrose, Gildas ^a   Gillet, Nicolas ^b   Rodriguez, Sabrina ^b   Boxus, Mathieu ^b   Verlaeten, Olivier ^b   Asquith, Becca ^c   Bangham, Charles ^c   Signaté, Aïssatou ^a   Smadja, Didier ^a   Lezin, Agnès ^a   Césaire, Raymond ^a   Willems, Luc ^b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; HLA DR ANTIGEN; VALPROIC ACID;

ADULT; AGED; ALOPECIA; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOLYSIS; DROWSINESS; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HTLV 1 ASSOCIATED MYELOPATHY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; LONG TERM CARE; MALE; PRIORITY JOURNAL; REACTION TIME; SCORING SYSTEM; TASK PERFORMANCE; TREMOR; TROPICAL SPASTIC PARAPARESIS; VERTIGO; VIRUS LOAD; WALKING; WALKING DIFFICULTY;

EID: 83455210438     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-349910     Document Type: Article

References (12)

1. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7(4):270-280. (Pubitemid 46480972)
2. Asquith B, Bangham CR. How does HTLV-I persist despite a strong cell-mediated immune response? Trends Immunol. 2008;29(1):4-11.
3. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol. 1998;4(6):586-593. (Pubitemid 29042065)
4. Olindo S, Cabre P, Lezin A, et al. Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study. Arch Neurol. 2006;63(11):1560-1566. (Pubitemid 44748798)
5. Achachi A, Florins A, Gillet N, et al. Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo. Proc Natl Acad Sci U S A. 2005;102(29):10309-10314. (Pubitemid 41023367)
6. Lezin A, Gillet N, Olindo S, et al. Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1-associated myelopathy/ tropical spastic paraparesis patients. Blood. 2007;110(10):3722- 3728. (Pubitemid 350159642)
7. Defoiche J, Debacq C, Asquith B, et al. Reduction of B cell turnover in chronic lymphocytic leukaemia. Br J Haematol. 2008;143(2):240-247.
8. Mosley AJ, Meekings KN, McCarthy C, et al. Histone deacetylase inhibitors increase virus gene expression but decrease CD8+ cell antiviral function in HTLV-1 infection. Blood. 2006;108(12): 3801-3807. (Pubitemid 44864562)
9. Asquith B, Mosley AJ, Barfield A, et al. A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load. J Gen Virol. 2005;86(5):1515-1523. (Pubitemid 40613271)
10. Dehee A, Cesaire R, Desire N, et al. Quantitation of HTLV-I proviral load by a TaqMan real-time PCR assay. J Virol Methods. 2002;102(1):37-51. (Pubitemid 34185468)
11. Afonso PV, Mekaouche M, Mortreux F, et al. Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. Blood. 2010;116(19):3802-3808.
12. Ramos J, Toomey N, Diaz L, Ruiz P, Barber G, Harrington W. Targeting HTLV-I latency in adult T-cell leukemia/lymphoma. Retrovirology. 2011;8: A48.